Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The United Laboratories International Holdings ( (HK:3933) ) has issued an announcement.
The United Laboratories International Holdings Limited announced the successful completion of a Phase II clinical trial for its TUL01101 Tablets, a JAK1 inhibitor, in treating moderate-to-severe atopic dermatitis in adults. The trial demonstrated significant efficacy and a positive safety profile, paving the way for a Phase III trial in China, which could enhance the company’s positioning in the autoimmune disease treatment market.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. It focuses on the development and production of new drugs, with a market focus on autoimmune diseases such as atopic dermatitis and rheumatoid arthritis.
YTD Price Performance: 5.97%
Average Trading Volume: 14,857,653
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.8B
Learn more about 3933 stock on TipRanks’ Stock Analysis page.